Q-omics provides the consensus-scored MIR33B profile across patient tissues and cancer cell-line models. MIR33B expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MIR33B is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, MIR33B RNA expression shows 6,352 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, KIRC, and UVM as cancer lineages where MIR33B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR33B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR33B survival associations across molecular data types. MIR33B RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR33B RNA expression–survival associations across cancer types. High MIR33B expression shows unfavorable associations in LUSC, KIRP, TGCT, SKCM, COAD and LIHC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LUSC as the clearest survival context for MIR33B RNA expression.
This table summarizes MIR33B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR33B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR33B shows higher tumor expression in KIRC, KICH, COAD and BRCA. The KIRC box plot shows higher MIR33B RNA expression in tumor versus normal tissue (log2 FC = +0.134, t-test p = .002).
This table shows molecular features associated with MIR33B in patient tissues and cancer cell lines. In patient samples, MIR33B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
